| Ticker | Action | Number of Shares Bought/Sold | Value of Shares Added/Sold | Average Price paid for previous share BUYs |
|---|
| - - | HOLD | 0 @ USD 0 | USD 0 | The current share valuation price of - based on adjusted close was USD 0. The average price that - shares were previous bought at was USD 0.00279608. The current market price is -100.0% lower than average price they were purchased at. USD 0 compared to the previous valuation of however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| 007390.KQ - NatureCell Co.,Ltd. | HOLD | 0 @ KRW 14.8133 | KRW 0 | The current share valuation price of 007390.KQ based on adjusted close was KRW 14.8133. The average price that 007390.KQ shares were previous bought at was KRW 21.4176. The current market price is -30.8% lower than average price they were purchased at. The value of the holding in 007390.KQ has fallen by KRW 31,740 (USD $22) compared to the previous valuation of NatureCell Co.,Ltd. |
| 039200.KQ - Oscotec Inc. | HOLD | 0 @ KRW 34.0909 | KRW 0 | The current share valuation price of 039200.KQ based on adjusted close was KRW 34.0909. The average price that 039200.KQ shares were previous bought at was KRW 21.0043. The current market price is 62.3% higher than average price they were purchased at. The value of the holding in 039200.KQ has fallen by KRW 31,887 (USD $22) compared to the previous valuation of Oscotec Inc. |
| 068270.KS - CELLTRION INC | HOLD | 0 @ KRW 123.174 | KRW 0 | The current share valuation price of 068270.KS based on adjusted close was KRW 123.174. The average price that 068270.KS shares were previous bought at was KRW 121.694. The current market price is 1.2% higher than average price they were purchased at. The value of the holding in 068270.KS has fallen by KRW 234,265 (USD $159) compared to the previous valuation of CELLTRION INC |
| 096530.KQ - Seegene, Inc. | HOLD | 0 @ KRW 16.4367 | KRW 0 | The current share valuation price of 096530.KQ based on adjusted close was KRW 16.4367. The average price that 096530.KQ shares were previous bought at was KRW 17.6933. The current market price is -7.1% lower than average price they were purchased at. The value of the holding in 096530.KQ has fallen by KRW 6,801 (USD $5) compared to the previous valuation of Seegene, Inc. |
| 13.HK - HUTCHMED (CHINA) LTD | HOLD | 0 @ HKD 2.66312 | HKD 0 | The current share valuation price of 13.HK based on adjusted close was HKD 2.66312. The average price that 13.HK shares were previous bought at was HKD 3.01399. The current market price is -11.6% lower than average price they were purchased at. The value of the holding in 13.HK has increased by HKD 14,952 (USD $1,922) compared to the previous valuation of HUTCHMED (CHINA) LTD however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| 182400.KQ - NKMAX LTD | HOLD | 0 @ KRW 3.89406 | KRW 0 | |
| 1877.HK - SHANGHAI JUNSHI BIOSCIENCES LTD H | HOLD | 0 @ HKD 2.88933 | HKD 0 | The current share valuation price of 1877.HK based on adjusted close was HKD 2.88933. The average price that 1877.HK shares were previous bought at was HKD 2.51798. The current market price is 14.7% higher than average price they were purchased at. The value of the holding in 1877.HK has fallen by HKD 12,248 (USD $1,574) compared to the previous valuation of SHANGHAI JUNSHI BIOSCIENCES LTD H |
| 207940.KS - SAMSUNG BIOLOGICS LTD | HOLD | 0 @ KRW 1175.6 | KRW 0 | The current share valuation price of 207940.KS based on adjusted close was KRW 1175.6. The average price that 207940.KS shares were previous bought at was KRW 760.081. The current market price is 54.7% higher than average price they were purchased at. The value of the holding in 207940.KS has fallen by KRW 90,383 (USD $61) compared to the previous valuation of SAMSUNG BIOLOGICS LTD |
| 2162.HK - KEYMED BIOSCIENCES INC | HOLD | 0 @ HKD 6.902 | HKD 0 | The current share valuation price of 2162.HK based on adjusted close was HKD 6.902. The average price that 2162.HK shares were previous bought at was HKD 5.35965. The current market price is 28.8% higher than average price they were purchased at. The value of the holding in 2162.HK has fallen by HKD 20,430 (USD $2,626) compared to the previous valuation of KEYMED BIOSCIENCES INC |
| 2252.HK - SHANGHAI MICROPORT MEDBOT CLASS H | HOLD | 0 @ HKD 2.66569 | HKD 0 | The current share valuation price of 2252.HK based on adjusted close was HKD 2.66569. The average price that 2252.HK shares were previous bought at was HKD 3.16268. The current market price is -15.7% lower than average price they were purchased at. The value of the holding in 2252.HK has increased by HKD 36,173 (USD $4,650) compared to the previous valuation of SHANGHAI MICROPORT MEDBOT CLASS H however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| 237690.KQ - ST Pharm Co.,Ltd. | HOLD | 0 @ KRW 86.8507 | KRW 0 | The current share valuation price of 237690.KQ based on adjusted close was KRW 86.8507. The average price that 237690.KQ shares were previous bought at was KRW 55.5458. The current market price is 56.4% higher than average price they were purchased at. The value of the holding in 237690.KQ has increased by KRW 7,327 (USD $5) compared to the previous valuation of ST Pharm Co.,Ltd. however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| 298380.KQ - ABL Bio Inc. | HOLD | 0 @ KRW 126.218 | KRW 0 | The current share valuation price of 298380.KQ based on adjusted close was KRW 126.218. The average price that 298380.KQ shares were previous bought at was KRW 40.1877. The current market price is 214.1% higher than average price they were purchased at. The value of the holding in 298380.KQ has increased by KRW 134,454 (USD $91) compared to the previous valuation of ABL Bio Inc. however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| 302440.KS - SK BIOSCIENCE LTD | HOLD | 0 @ KRW 34.0233 | KRW 0 | The current share valuation price of 302440.KS based on adjusted close was KRW 34.0233. The average price that 302440.KS shares were previous bought at was KRW 36.2275. The current market price is -6.1% lower than average price they were purchased at. The value of the holding in 302440.KS has fallen by KRW 20,521 (USD $14) compared to the previous valuation of SK BIOSCIENCE LTD |
| 326030.KS - SK BIOPHARMACEUTICALS LTD | HOLD | 0 @ KRW 87.2565 | KRW 0 | The current share valuation price of 326030.KS based on adjusted close was KRW 87.2565. The average price that 326030.KS shares were previous bought at was KRW 77.4592. The current market price is 12.6% higher than average price they were purchased at. The value of the holding in 326030.KS has fallen by KRW 43,876 (USD $30) compared to the previous valuation of SK BIOPHARMACEUTICALS LTD |
| 328130.KQ - Lunit Inc. | HOLD | 0 @ KRW 24.9256 | KRW 0 | The current share valuation price of 328130.KQ based on adjusted close was KRW 24.9256. The average price that 328130.KQ shares were previous bought at was KRW 36.3011. The current market price is -31.3% lower than average price they were purchased at. The value of the holding in 328130.KQ has fallen by KRW 9,217 (USD $6) compared to the previous valuation of Lunit Inc. |
| 3933.HK - THE UNITED LABORATORIES INTERNATIO | HOLD | 0 @ HKD 1.55777 | HKD 0 | The current share valuation price of 3933.HK based on adjusted close was HKD 1.55777. The average price that 3933.HK shares were previous bought at was HKD 1.67688. The current market price is -7.1% lower than average price they were purchased at. The value of the holding in 3933.HK has increased by HKD 9,329 (USD $1,199) compared to the previous valuation of THE UNITED LABORATORIES INTERNATIO however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| 4523.T - Eisai Co., Ltd. | HOLD | 0 @ JPY 29.4641 | JPY 0 | The current share valuation price of 4523.T based on adjusted close was JPY 29.4641. The average price that 4523.T shares were previous bought at was JPY 28.5269. The current market price is 3.3% higher than average price they were purchased at. The value of the holding in 4523.T has increased by JPY 146,018 (USD $939) compared to the previous valuation of Eisai Co., Ltd. however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| 4549.T - Eiken Chemical Co., Ltd. | HOLD | 0 @ JPY 15.8089 | JPY 0 | The current share valuation price of 4549.T based on adjusted close was JPY 15.8089. The average price that 4549.T shares were previous bought at was JPY 13.728. The current market price is 15.2% higher than average price they were purchased at. The value of the holding in 4549.T has increased by JPY 9,568 (USD $62) compared to the previous valuation of Eiken Chemical Co., Ltd. however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| 4587.T - PeptiDream Inc. | HOLD | 0 @ JPY 10.9743 | JPY 0 | The current share valuation price of 4587.T based on adjusted close was JPY 10.9743. The average price that 4587.T shares were previous bought at was JPY 11.127. The current market price is -1.4% lower than average price they were purchased at. The value of the holding in 4587.T has increased by JPY 21,168 (USD $136) compared to the previous valuation of PeptiDream Inc. however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| 4887.T - Sawai Group Holdings Co., Ltd. | HOLD | 0 @ JPY 15.2303 | JPY 0 | The current share valuation price of 4887.T based on adjusted close was JPY 15.2303. The average price that 4887.T shares were previous bought at was JPY 13.195. The current market price is 15.4% higher than average price they were purchased at. The value of the holding in 4887.T has increased by JPY 19,451 (USD $125) compared to the previous valuation of Sawai Group Holdings Co., Ltd. however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| 4974.T - Takara Bio Inc. | HOLD | 0 @ JPY 5.05319 | JPY 0 | The current share valuation price of 4974.T based on adjusted close was JPY 5.05319. The average price that 4974.T shares were previous bought at was JPY 5.75157. The current market price is -12.1% lower than average price they were purchased at. The value of the holding in 4974.T has increased by JPY 5,454 (USD $35) compared to the previous valuation of Takara Bio Inc. however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| 6869.T - Sysmex Corporation | HOLD | 0 @ JPY 10.0325 | JPY 0 | The current share valuation price of 6869.T based on adjusted close was JPY 10.0325. The average price that 6869.T shares were previous bought at was JPY 14.9756. The current market price is -33.0% lower than average price they were purchased at. The value of the holding in 6869.T has increased by JPY 151,855 (USD $977) compared to the previous valuation of Sysmex Corporation however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| 6951.T - JEOL Ltd. | HOLD | 0 @ JPY 30.8271 | JPY 0 | The current share valuation price of 6951.T based on adjusted close was JPY 30.8271. The average price that 6951.T shares were previous bought at was JPY 33.0489. The current market price is -6.7% lower than average price they were purchased at. The value of the holding in 6951.T has increased by JPY 10,644 (USD $68) compared to the previous valuation of JEOL Ltd. however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| 7575.T - Japan Lifeline Co., Ltd. | HOLD | 0 @ JPY 9.96496 | JPY 0 | The current share valuation price of 7575.T based on adjusted close was JPY 9.96496. The average price that 7575.T shares were previous bought at was JPY 10.1423. The current market price is -1.7% lower than average price they were purchased at. The value of the holding in 7575.T has increased by JPY 3,087 (USD $20) compared to the previous valuation of Japan Lifeline Co., Ltd. however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| 7701.T - Shimadzu Corporation | HOLD | 0 @ JPY 27.394 | JPY 0 | The current share valuation price of 7701.T based on adjusted close was JPY 27.394. The average price that 7701.T shares were previous bought at was JPY 26.4723. The current market price is 3.5% higher than average price they were purchased at. The value of the holding in 7701.T has fallen by JPY 136,131 (USD $875) compared to the previous valuation of Shimadzu Corporation |
| 7747.T - Asahi Intecc Co., Ltd. | HOLD | 0 @ JPY 19.4092 | JPY 0 | The current share valuation price of 7747.T based on adjusted close was JPY 19.4092. The average price that 7747.T shares were previous bought at was JPY 16.8906. The current market price is 14.9% higher than average price they were purchased at. The value of the holding in 7747.T has increased by JPY 16,898 (USD $109) compared to the previous valuation of Asahi Intecc Co., Ltd. however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| 9995.HK - REMEGEN LTD H | HOLD | 0 @ HKD 9.85817 | HKD 0 | The current share valuation price of 9995.HK based on adjusted close was HKD 9.85817. The average price that 9995.HK shares were previous bought at was HKD 9.70899. The current market price is 1.5% higher than average price they were purchased at. The value of the holding in 9995.HK has fallen by HKD 21,366 (USD $2,747) compared to the previous valuation of REMEGEN LTD H |
| A - Agilent Technologies Inc | HOLD | 0 @ USD 136.9 | USD 0 | The current share valuation price of A based on adjusted close was USD 136.9. The average price that A shares were previous bought at was USD 122.269. The current market price is 12.0% higher than average price they were purchased at. The value of the holding in A has increased by USD 30,017 compared to the previous valuation of Agilent Technologies Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| ABBV - AbbVie Inc | HOLD | 0 @ USD 222.82 | USD 0 | The current share valuation price of ABBV based on adjusted close was USD 222.82. The average price that ABBV shares were previous bought at was USD 201.245. The current market price is 10.7% higher than average price they were purchased at. The value of the holding in ABBV has fallen by USD 118,522 compared to the previous valuation of AbbVie Inc |
| ABCL - Abcellera Biologics Inc | HOLD | 0 @ USD 3.53 | USD 0 | The current share valuation price of ABCL based on adjusted close was USD 3.53. The average price that ABCL shares were previous bought at was USD 3.61385. The current market price is -2.3% lower than average price they were purchased at. The value of the holding in ABCL has increased by USD 50,740 compared to the previous valuation of Abcellera Biologics Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| ABT - Abbott Laboratories | HOLD | 0 @ USD 125.12 | USD 0 | The current share valuation price of ABT based on adjusted close was USD 125.12. The average price that ABT shares were previous bought at was USD 124.674. The current market price is 0.4% higher than average price they were purchased at. The value of the holding in ABT has fallen by USD 178,684 compared to the previous valuation of Abbott Laboratories |
| ACAD - ACADIA Pharmaceuticals Inc | HOLD | 0 @ USD 26.6 | USD 0 | The current share valuation price of ACAD based on adjusted close was USD 26.6. The average price that ACAD shares were previous bought at was USD 20.1364. The current market price is 32.1% higher than average price they were purchased at. The value of the holding in ACAD has fallen by USD 50,321 compared to the previous valuation of ACADIA Pharmaceuticals Inc |
| ACLX - Arcellx Inc | HOLD | 0 @ USD 64.13 | USD 0 | The current share valuation price of ACLX based on adjusted close was USD 64.13. The average price that ACLX shares were previous bought at was USD 64.8725. The current market price is -1.1% lower than average price they were purchased at. The value of the holding in ACLX has fallen by USD 30,411 compared to the previous valuation of Arcellx Inc |
| ADPT - Adaptive Biotechnologies Corp | HOLD | 0 @ USD 16.5 | USD 0 | The current share valuation price of ADPT based on adjusted close was USD 16.5. The average price that ADPT shares were previous bought at was USD 6.89362. The current market price is 139.4% higher than average price they were purchased at. The value of the holding in ADPT has increased by USD 70,708 compared to the previous valuation of Adaptive Biotechnologies Corp however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| ALKS - Alkermes Plc | HOLD | 0 @ USD 27.81 | USD 0 | The current share valuation price of ALKS based on adjusted close was USD 27.81. The average price that ALKS shares were previous bought at was USD 30.7179. The current market price is -9.5% lower than average price they were purchased at. The value of the holding in ALKS has fallen by USD 46,437 compared to the previous valuation of Alkermes Plc |
| AMGN - Amgen Inc | HOLD | 0 @ USD 324.42 | USD 0 | The current share valuation price of AMGN based on adjusted close was USD 324.42. The average price that AMGN shares were previous bought at was USD 296.507. The current market price is 9.4% higher than average price they were purchased at. The value of the holding in AMGN has fallen by USD 81,679 compared to the previous valuation of Amgen Inc |
| AMLX - Amylyx Pharmaceuticals Inc | HOLD | 0 @ USD 11.92 | USD 0 | The current share valuation price of AMLX based on adjusted close was USD 11.92. The average price that AMLX shares were previous bought at was USD 13.5196. The current market price is -11.8% lower than average price they were purchased at. The value of the holding in AMLX has increased by USD 4,515 compared to the previous valuation of Amylyx Pharmaceuticals Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| ANAB - AnaptysBio Inc | HOLD | 0 @ USD 47.53 | USD 0 | The current share valuation price of ANAB based on adjusted close was USD 47.53. The average price that ANAB shares were previous bought at was USD 23.8129. The current market price is 99.6% higher than average price they were purchased at. The value of the holding in ANAB has increased by USD 48,426 compared to the previous valuation of AnaptysBio Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| ARCT - Arcturus Therapeutics Holdings Inc | HOLD | 0 @ USD 6.43 | USD 0 | The current share valuation price of ARCT based on adjusted close was USD 6.43. The average price that ARCT shares were previous bought at was USD 13.0207. The current market price is -50.6% lower than average price they were purchased at. The value of the holding in ARCT has fallen by USD 2,392 compared to the previous valuation of Arcturus Therapeutics Holdings Inc |
| ARVN - Arvinas Inc | HOLD | 0 @ USD 11.28 | USD 0 | The current share valuation price of ARVN based on adjusted close was USD 11.28. The average price that ARVN shares were previous bought at was USD 11.3626. The current market price is -0.7% lower than average price they were purchased at. The value of the holding in ARVN has fallen by USD 37,900 compared to the previous valuation of Arvinas Inc |
| ASTH - Astrana Health Inc | HOLD | 0 @ USD 23.21 | USD 0 | The current share valuation price of ASTH based on adjusted close was USD 23.21. The average price that ASTH shares were previous bought at was USD 26.5685. The current market price is -12.6% lower than average price they were purchased at. The value of the holding in ASTH has increased by USD 28,136 compared to the previous valuation of Astrana Health Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| ATRC - AtriCure Inc | HOLD | 0 @ USD 40.4 | USD 0 | The current share valuation price of ATRC based on adjusted close was USD 40.4. The average price that ATRC shares were previous bought at was USD 33.402. The current market price is 21.0% higher than average price they were purchased at. The value of the holding in ATRC has fallen by USD 24,785 compared to the previous valuation of AtriCure Inc |
| AUPH - Aurinia Pharmaceuticals Inc | HOLD | 0 @ USD 15.91 | USD 0 | The current share valuation price of AUPH based on adjusted close was USD 15.91. The average price that AUPH shares were previous bought at was USD 11.2153. The current market price is 41.9% higher than average price they were purchased at. The value of the holding in AUPH has increased by USD 19,474 compared to the previous valuation of Aurinia Pharmaceuticals Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| AXGN - Axogen Inc | HOLD | 0 @ USD 31.7 | USD 0 | The current share valuation price of AXGN based on adjusted close was USD 31.7. The average price that AXGN shares were previous bought at was USD 18.047. The current market price is 75.7% higher than average price they were purchased at. The value of the holding in AXGN has increased by USD 16,672 compared to the previous valuation of Axogen Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| AXSM - Axsome Therapeutics Inc | HOLD | 0 @ USD 147 | USD 0 | The current share valuation price of AXSM based on adjusted close was USD 147. The average price that AXSM shares were previous bought at was USD 116.831. The current market price is 25.8% higher than average price they were purchased at. The value of the holding in AXSM has fallen by USD 46,949 compared to the previous valuation of Axsome Therapeutics Inc |
| BANB.SW - | HOLD | 0 @ CHF 70.529 | CHF 0 | The current share valuation price of BANB.SW based on adjusted close was CHF 70.529. The average price that BANB.SW shares were previous bought at was CHF 65.0923. The current market price is 8.4% higher than average price they were purchased at. The value of the holding in BANB.SW has increased by CHF 93,178 (USD $117,176) compared to the previous valuation of however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| BAVA.CO - | HOLD | 0 @ DKK 29.5087 | DKK 0 | The current share valuation price of BAVA.CO based on adjusted close was DKK 29.5087. The average price that BAVA.CO shares were previous bought at was DKK 25.4205. The current market price is 16.1% higher than average price they were purchased at. The value of the holding in BAVA.CO has increased by DKK 59,536 (USD $9,358) compared to the previous valuation of however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| BCRX - BioCryst Pharmaceuticals Inc | HOLD | 0 @ USD 7.29 | USD 0 | The current share valuation price of BCRX based on adjusted close was USD 7.29. The average price that BCRX shares were previous bought at was USD 7.74854. The current market price is -5.9% lower than average price they were purchased at. The value of the holding in BCRX has increased by USD 42,103 compared to the previous valuation of BioCryst Pharmaceuticals Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| BEAM - Beam Therapeutics Inc | HOLD | 0 @ USD 26.17 | USD 0 | The current share valuation price of BEAM based on adjusted close was USD 26.17. The average price that BEAM shares were previous bought at was USD 18.6816. The current market price is 40.1% higher than average price they were purchased at. The value of the holding in BEAM has increased by USD 71,160 compared to the previous valuation of Beam Therapeutics Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| BIIB - Biogen Inc | HOLD | 0 @ USD 169.91 | USD 0 | The current share valuation price of BIIB based on adjusted close was USD 169.91. The average price that BIIB shares were previous bought at was USD 130.477. The current market price is 30.2% higher than average price they were purchased at. The value of the holding in BIIB has fallen by USD 243,646 compared to the previous valuation of Biogen Inc |
| BIM.PA - BioMerieux | HOLD | 0 @ EUR 127.238 | EUR 0 | The current share valuation price of BIM.PA based on adjusted close was EUR 127.238. The average price that BIM.PA shares were previous bought at was EUR 121.406. The current market price is 4.8% higher than average price they were purchased at. The value of the holding in BIM.PA has fallen by EUR 17,793 (USD $20,893) compared to the previous valuation of BioMerieux |
| BIO - Bio-Rad Laboratories Inc | HOLD | 0 @ USD 299.86 | USD 0 | The current share valuation price of BIO based on adjusted close was USD 299.86. The average price that BIO shares were previous bought at was USD 290.296. The current market price is 3.3% higher than average price they were purchased at. The value of the holding in BIO has fallen by USD 37,149 compared to the previous valuation of Bio-Rad Laboratories Inc |
| BIO - Biotest Aktiengesellschaft | HOLD | 0 @ USD 299.86 | USD 0 | The current share valuation price of BIO based on adjusted close was USD 299.86. The average price that BIO shares were previous bought at was USD 290.296. The current market price is 3.3% higher than average price they were purchased at. The value of the holding in BIO has fallen by USD 37,149 compared to the previous valuation of Biotest Aktiengesellschaft |
| BIOA-B.ST - | HOLD | 0 @ SEK 33.6623 | SEK 0 | The current share valuation price of BIOA-B.ST based on adjusted close was SEK 33.6623. The average price that BIOA-B.ST shares were previous bought at was SEK 29.997. The current market price is 12.2% higher than average price they were purchased at. The value of the holding in BIOA-B.ST has fallen by SEK 15,654 (USD $1,683) compared to the previous valuation of |
| BLFS - BioLife Solutions Inc | HOLD | 0 @ USD 25.34 | USD 0 | The current share valuation price of BLFS based on adjusted close was USD 25.34. The average price that BLFS shares were previous bought at was USD 25.7305. The current market price is -1.5% lower than average price they were purchased at. The value of the holding in BLFS has increased by USD 18,928 compared to the previous valuation of BioLife Solutions Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| BMY - Bloomsbury Publishing Plc | HOLD | 0 @ USD 53.33 | USD 0 | The current share valuation price of BMY based on adjusted close was USD 53.33. The average price that BMY shares were previous bought at was USD 53.3317. The current market price is 0.0% lower than average price they were purchased at. The value of the holding in BMY has fallen by USD 66,363 compared to the previous valuation of Bloomsbury Publishing Plc |
| BSX - Boston Scientific Corporation | HOLD | 0 @ USD 96.11 | USD 0 | The current share valuation price of BSX based on adjusted close was USD 96.11. The average price that BSX shares were previous bought at was USD 97.6281. The current market price is -1.6% lower than average price they were purchased at. The value of the holding in BSX has increased by USD 247,409 compared to the previous valuation of Boston Scientific Corporation however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| BSX - MULSTRXSSXIMETFP | HOLD | 0 @ USD 96.11 | USD 0 | The current share valuation price of BSX based on adjusted close was USD 96.11. The average price that BSX shares were previous bought at was USD 97.6281. The current market price is -1.6% lower than average price they were purchased at. The value of the holding in BSX has increased by USD 247,409 compared to the previous valuation of MULSTRXSSXIMETFP however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| CDNA - Caredx Inc | HOLD | 0 @ USD 19.19 | USD 0 | The current share valuation price of CDNA based on adjusted close was USD 19.19. The average price that CDNA shares were previous bought at was USD 19.212. The current market price is -0.1% lower than average price they were purchased at. The value of the holding in CDNA has fallen by USD 18,886 compared to the previous valuation of Caredx Inc |
| CERT - Certara Inc | HOLD | 0 @ USD 8.88 | USD 0 | The current share valuation price of CERT based on adjusted close was USD 8.88. The average price that CERT shares were previous bought at was USD 10.4074. The current market price is -14.7% lower than average price they were purchased at. The value of the holding in CERT has increased by USD 2,857 compared to the previous valuation of Certara Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| CGON - CG Oncology, Inc. Common stock | HOLD | 0 @ USD 38 | USD 0 | The current share valuation price of CGON based on adjusted close was USD 38. The average price that CGON shares were previous bought at was USD 41.6925. The current market price is -8.9% lower than average price they were purchased at. The value of the holding in CGON has increased by USD 47,784 compared to the previous valuation of CG Oncology, Inc. Common stock however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| CHEMM.CO - | HOLD | 0 @ DKK 104.379 | DKK 0 | The current share valuation price of CHEMM.CO based on adjusted close was DKK 104.379. The average price that CHEMM.CO shares were previous bought at was DKK 78.2284. The current market price is 33.4% higher than average price they were purchased at. The value of the holding in CHEMM.CO has increased by DKK 43,864 (USD $6,895) compared to the previous valuation of however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| CPRX - Catalyst Pharmaceuticals Inc | HOLD | 0 @ USD 23.67 | USD 0 | The current share valuation price of CPRX based on adjusted close was USD 23.67. The average price that CPRX shares were previous bought at was USD 22.4325. The current market price is 5.5% higher than average price they were purchased at. The value of the holding in CPRX has fallen by USD 49,795 compared to the previous valuation of Catalyst Pharmaceuticals Inc |
| CRL - Creightons Plc | HOLD | 0 @ USD 193.85 | USD 0 | The current share valuation price of CRL based on adjusted close was USD 193.85. The average price that CRL shares were previous bought at was USD 165.907. The current market price is 16.8% higher than average price they were purchased at. The value of the holding in CRL has fallen by USD 128,365 compared to the previous valuation of Creightons Plc |
| CRVL - CorVel Corp | HOLD | 0 @ USD 70.24 | USD 0 | The current share valuation price of CRVL based on adjusted close was USD 70.24. The average price that CRVL shares were previous bought at was USD 111.522. The current market price is -37.0% lower than average price they were purchased at. The value of the holding in CRVL has fallen by USD 21,419 compared to the previous valuation of CorVel Corp |
| CSTL - Castle Biosciences Inc | HOLD | 0 @ USD 39.6 | USD 0 | The current share valuation price of CSTL based on adjusted close was USD 39.6. The average price that CSTL shares were previous bought at was USD 21.3129. The current market price is 85.8% higher than average price they were purchased at. The value of the holding in CSTL has fallen by USD 2,122 compared to the previous valuation of Castle Biosciences Inc |
| CTKB - Cytek Biosciences Inc | HOLD | 0 @ USD 4.8 | USD 0 | The current share valuation price of CTKB based on adjusted close was USD 4.8. The average price that CTKB shares were previous bought at was USD 5.7145. The current market price is -16.0% lower than average price they were purchased at. The value of the holding in CTKB has fallen by USD 1,607 compared to the previous valuation of Cytek Biosciences Inc |
| DAWN - Day One Biopharmaceuticals Inc | HOLD | 0 @ USD 9.97 | USD 0 | The current share valuation price of DAWN based on adjusted close was USD 9.97. The average price that DAWN shares were previous bought at was USD 8.3429. The current market price is 19.5% higher than average price they were purchased at. The value of the holding in DAWN has increased by USD 112,962 compared to the previous valuation of Day One Biopharmaceuticals Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| DHR - Danaher Corporation | HOLD | 0 @ USD 224.35 | USD 0 | The current share valuation price of DHR based on adjusted close was USD 224.35. The average price that DHR shares were previous bought at was USD 199.979. The current market price is 12.2% higher than average price they were purchased at. The value of the holding in DHR has increased by USD 127,956 compared to the previous valuation of Danaher Corporation however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| DHR - Danaher Corporation | HOLD | 0 @ USD 224.35 | USD 0 | The current share valuation price of DHR based on adjusted close was USD 224.35. The average price that DHR shares were previous bought at was USD 199.979. The current market price is 12.2% higher than average price they were purchased at. The value of the holding in DHR has increased by USD 127,956 compared to the previous valuation of Danaher Corporation however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| DIA.MI - DiaSorin SpA | HOLD | 0 @ EUR 74.7479 | EUR 0 | The current share valuation price of DIA.MI based on adjusted close was EUR 74.7479. The average price that DIA.MI shares were previous bought at was EUR 54.1257. The current market price is 38.1% higher than average price they were purchased at. The value of the holding in DIA.MI has fallen by EUR 15,310 (USD $17,978) compared to the previous valuation of DiaSorin SpA |
| DVAX - Dynavax Technologies Corporation | HOLD | 0 @ USD 10.87 | USD 0 | The current share valuation price of DVAX based on adjusted close was USD 10.87. The average price that DVAX shares were previous bought at was USD 12.6313. The current market price is -13.9% lower than average price they were purchased at. The value of the holding in DVAX has increased by USD 11,587 compared to the previous valuation of Dynavax Technologies Corporation however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| DXCM - DexCom Inc | HOLD | 0 @ USD 65.91 | USD 0 | The current share valuation price of DXCM based on adjusted close was USD 65.91. The average price that DXCM shares were previous bought at was USD 78.8148. The current market price is -16.4% lower than average price they were purchased at. The value of the holding in DXCM has increased by USD 28,434 compared to the previous valuation of DexCom Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| DYVOX.ST - | HOLD | 0 @ SEK 10.6447 | SEK 0 | The current share valuation price of DYVOX.ST based on adjusted close was SEK 10.6447. The average price that DYVOX.ST shares were previous bought at was SEK 6.29712. The current market price is 69.0% higher than average price they were purchased at. The value of the holding in DYVOX.ST has increased by SEK 44,192 (USD $4,753) compared to the previous valuation of however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| EKTA-B.ST - | HOLD | 0 @ SEK 6.07343 | SEK 0 | The current share valuation price of EKTA-B.ST based on adjusted close was SEK 6.07343. The average price that EKTA-B.ST shares were previous bought at was SEK 5.63298. The current market price is 7.8% higher than average price they were purchased at. The value of the holding in EKTA-B.ST has fallen by SEK 1,604 (USD $172) compared to the previous valuation of |
| EMBC - Embecta Corp | HOLD | 0 @ USD 11.71 | USD 0 | The current share valuation price of EMBC based on adjusted close was USD 11.71. The average price that EMBC shares were previous bought at was USD 13.0183. The current market price is -10.0% lower than average price they were purchased at. The value of the holding in EMBC has fallen by USD 4,932 compared to the previous valuation of Embecta Corp |
| EUZ.DE - Eckert & Ziegler SE | HOLD | 0 @ EUR 16.9807 | EUR 0 | The current share valuation price of EUZ.DE based on adjusted close was EUR 16.9807. The average price that EUZ.DE shares were previous bought at was EUR 18.7965. The current market price is -9.7% lower than average price they were purchased at. The value of the holding in EUZ.DE has fallen by EUR 12,637 (USD $14,839) compared to the previous valuation of Eckert & Ziegler SE |
| EVH - Evolent Health Inc | HOLD | 0 @ USD 3.97 | USD 0 | The current share valuation price of EVH based on adjusted close was USD 3.97. The average price that EVH shares were previous bought at was USD 9.55347. The current market price is -58.4% lower than average price they were purchased at. The value of the holding in EVH has fallen by USD 9,080 compared to the previous valuation of Evolent Health Inc |
| EVT.DE - Evotec SE | HOLD | 0 @ EUR 6.03237 | EUR 0 | The current share valuation price of EVT.DE based on adjusted close was EUR 6.03237. The average price that EVT.DE shares were previous bought at was EUR 6.56761. The current market price is -8.1% lower than average price they were purchased at. The value of the holding in EVT.DE has fallen by EUR 8,209 (USD $9,639) compared to the previous valuation of Evotec SE |
| EW - Edwards Lifesciences Corp | HOLD | 0 @ USD 84.8 | USD 0 | The current share valuation price of EW based on adjusted close was USD 84.8. The average price that EW shares were previous bought at was USD 74.591. The current market price is 13.7% higher than average price they were purchased at. The value of the holding in EW has fallen by USD 7,955 compared to the previous valuation of Edwards Lifesciences Corp |
| EXAS - EXACT Sciences Corporation | HOLD | 0 @ USD 101.38 | USD 0 | The current share valuation price of EXAS based on adjusted close was USD 101.38. The average price that EXAS shares were previous bought at was USD 62.0439. The current market price is 63.4% higher than average price they were purchased at. The value of the holding in EXAS has fallen by USD 53,185 compared to the previous valuation of EXACT Sciences Corporation |
| EXEL - Exelixis Inc | HOLD | 0 @ USD 42.57 | USD 0 | The current share valuation price of EXEL based on adjusted close was USD 42.57. The average price that EXEL shares were previous bought at was USD 38.1215. The current market price is 11.7% higher than average price they were purchased at. The value of the holding in EXEL has increased by USD 190,548 compared to the previous valuation of Exelixis Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| FTRE - Fortrea Holdings Inc. | HOLD | 0 @ USD 16.61 | USD 0 | The current share valuation price of FTRE based on adjusted close was USD 16.61. The average price that FTRE shares were previous bought at was USD 10.5322. The current market price is 57.7% higher than average price they were purchased at. The value of the holding in FTRE has increased by USD 47,526 compared to the previous valuation of Fortrea Holdings Inc. however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| GH - Guardant Health Inc | HOLD | 0 @ USD 97.1 | USD 0 | The current share valuation price of GH based on adjusted close was USD 97.1. The average price that GH shares were previous bought at was USD 54.9629. The current market price is 76.7% higher than average price they were purchased at. The value of the holding in GH has fallen by USD 56,190 compared to the previous valuation of Guardant Health Inc |
| GILD - Guild Esports Plc | HOLD | 0 @ USD 121.47 | USD 0 | The current share valuation price of GILD based on adjusted close was USD 121.47. The average price that GILD shares were previous bought at was USD 107.342. The current market price is 13.2% higher than average price they were purchased at. The value of the holding in GILD has increased by USD 15,061 compared to the previous valuation of Guild Esports Plc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| GLPG.AS - Galapagos NV | HOLD | 0 @ EUR 31.616 | EUR 0 | The current share valuation price of GLPG.AS based on adjusted close was EUR 31.616. The average price that GLPG.AS shares were previous bought at was EUR 29.0814. The current market price is 8.7% higher than average price they were purchased at. The value of the holding in GLPG.AS has increased by EUR 3,092 (USD $3,631) compared to the previous valuation of Galapagos NV however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| GMAB.CO - | HOLD | 0 @ DKK 314.55 | DKK 0 | The current share valuation price of GMAB.CO based on adjusted close was DKK 314.55. The average price that GMAB.CO shares were previous bought at was DKK 222.447. The current market price is 41.4% higher than average price they were purchased at. The value of the holding in GMAB.CO has fallen by DKK 202,564 (USD $31,839) compared to the previous valuation of |
| GSK.L - GlaxoSmithKline PLC | HOLD | 0 @ GBP 24.2766 | GBP 0 | The current share valuation price of GSK.L based on adjusted close was GBP 24.2766. The average price that GSK.L shares were previous bought at was GBP 19.3589. The current market price is 25.4% higher than average price they were purchased at. The value of the holding in GSK.L has fallen by GBP 215,521 (USD $288,251) compared to the previous valuation of GlaxoSmithKline PLC |
| HALO - Halozyme Therapeutics Inc | HOLD | 0 @ USD 65.11 | USD 0 | The current share valuation price of HALO based on adjusted close was USD 65.11. The average price that HALO shares were previous bought at was USD 60.3305. The current market price is 7.9% higher than average price they were purchased at. The value of the holding in HALO has fallen by USD 99,691 compared to the previous valuation of Halozyme Therapeutics Inc |
| HLUN-B.CO - | HOLD | 0 @ DKK 6.73678 | DKK 0 | The current share valuation price of HLUN-B.CO based on adjusted close was DKK 6.73678. The average price that HLUN-B.CO shares were previous bought at was DKK 6.0023. The current market price is 12.2% higher than average price they were purchased at. The value of the holding in HLUN-B.CO has increased by DKK 1,160 (USD $182) compared to the previous valuation of however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| HOLX - Hologic Inc | HOLD | 0 @ USD 74.94 | USD 0 | The current share valuation price of HOLX based on adjusted close was USD 74.94. The average price that HOLX shares were previous bought at was USD 66.2934. The current market price is 13.0% higher than average price they were purchased at. The value of the holding in HOLX has increased by USD 2,314 compared to the previous valuation of Hologic Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| HRMY - Harmony Biosciences Holdings | HOLD | 0 @ USD 37.47 | USD 0 | The current share valuation price of HRMY based on adjusted close was USD 37.47. The average price that HRMY shares were previous bought at was USD 32.6637. The current market price is 14.7% higher than average price they were purchased at. The value of the holding in HRMY has fallen by USD 70,516 compared to the previous valuation of Harmony Biosciences Holdings |
| IART - Integra LifeSciences Holdings | HOLD | 0 @ USD 13.05 | USD 0 | The current share valuation price of IART based on adjusted close was USD 13.05. The average price that IART shares were previous bought at was USD 20.1099. The current market price is -35.1% lower than average price they were purchased at. The value of the holding in IART has increased by USD 823 compared to the previous valuation of Integra LifeSciences Holdings however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| IBRX - Immunitybio Inc | HOLD | 0 @ USD 2.09 | USD 0 | The current share valuation price of IBRX based on adjusted close was USD 2.09. The average price that IBRX shares were previous bought at was USD 2.81966. The current market price is -25.9% lower than average price they were purchased at. The value of the holding in IBRX has fallen by USD 5,616 compared to the previous valuation of Immunitybio Inc |
| IDYA - Ideaya Biosciences Inc | HOLD | 0 @ USD 33.26 | USD 0 | The current share valuation price of IDYA based on adjusted close was USD 33.26. The average price that IDYA shares were previous bought at was USD 23.8167. The current market price is 39.6% higher than average price they were purchased at. The value of the holding in IDYA has fallen by USD 50,824 compared to the previous valuation of Ideaya Biosciences Inc |
| ILMN - Illumina Inc | HOLD | 0 @ USD 130.51 | USD 0 | The current share valuation price of ILMN based on adjusted close was USD 130.51. The average price that ILMN shares were previous bought at was USD 95.299. The current market price is 36.9% higher than average price they were purchased at. The value of the holding in ILMN has increased by USD 162,765 compared to the previous valuation of Illumina Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| IOVA - Iovance Biotherapeutics Inc | HOLD | 0 @ USD 2.46 | USD 0 | The current share valuation price of IOVA based on adjusted close was USD 2.46. The average price that IOVA shares were previous bought at was USD 2.41138. The current market price is 2.0% higher than average price they were purchased at. The value of the holding in IOVA has fallen by USD 20,359 compared to the previous valuation of Iovance Biotherapeutics Inc |
| IPN.PA - Ipsen SA | HOLD | 0 @ EUR 140.841 | EUR 0 | The current share valuation price of IPN.PA based on adjusted close was EUR 140.841. The average price that IPN.PA shares were previous bought at was EUR 120.641. The current market price is 16.7% higher than average price they were purchased at. The value of the holding in IPN.PA has fallen by EUR 14,654 (USD $17,207) compared to the previous valuation of Ipsen SA |
| IQV - IQVIA Holdings Inc | HOLD | 0 @ USD 222.52 | USD 0 | The current share valuation price of IQV based on adjusted close was USD 222.52. The average price that IQV shares were previous bought at was USD 162.435. The current market price is 37.0% higher than average price they were purchased at. The value of the holding in IQV has increased by USD 102,838 compared to the previous valuation of IQVIA Holdings Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| ISRG - Intuitive Surgical Inc | HOLD | 0 @ USD 561.89 | USD 0 | The current share valuation price of ISRG based on adjusted close was USD 561.89. The average price that ISRG shares were previous bought at was USD 536.021. The current market price is 4.8% higher than average price they were purchased at. The value of the holding in ISRG has increased by USD 143,169 compared to the previous valuation of Intuitive Surgical Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| JANX - Janux Therapeutics Inc | HOLD | 0 @ USD 14.04 | USD 0 | The current share valuation price of JANX based on adjusted close was USD 14.04. The average price that JANX shares were previous bought at was USD 24.7281. The current market price is -43.2% lower than average price they were purchased at. The value of the holding in JANX has fallen by USD 4,214 compared to the previous valuation of Janux Therapeutics Inc |
| JNJ - Johnson & Johnson | HOLD | 0 @ USD 208.31 | USD 0 | The current share valuation price of JNJ based on adjusted close was USD 208.31. The average price that JNJ shares were previous bought at was USD 170.984. The current market price is 21.8% higher than average price they were purchased at. The value of the holding in JNJ has fallen by USD 194,623 compared to the previous valuation of Johnson & Johnson |
| KNSA - Kiniksa Pharmaceuticals Ltd | HOLD | 0 @ USD 42 | USD 0 | The current share valuation price of KNSA based on adjusted close was USD 42. The average price that KNSA shares were previous bought at was USD 40.3374. The current market price is 4.1% higher than average price they were purchased at. The value of the holding in KNSA has increased by USD 28,164 compared to the previous valuation of Kiniksa Pharmaceuticals Ltd however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| KURA - Kura Oncology Inc | HOLD | 0 @ USD 9.85 | USD 0 | The current share valuation price of KURA based on adjusted close was USD 9.85. The average price that KURA shares were previous bought at was USD 10.711. The current market price is -8.0% lower than average price they were purchased at. The value of the holding in KURA has fallen by USD 31,618 compared to the previous valuation of Kura Oncology Inc |
| LAB - Standard Biotools Inc | HOLD | 0 @ USD 1.66 | USD 0 | The current share valuation price of LAB based on adjusted close was USD 1.66. The average price that LAB shares were previous bought at was USD 1.39779. The current market price is 18.8% higher than average price they were purchased at. The value of the holding in LAB has increased by USD 46,599 compared to the previous valuation of Standard Biotools Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| LGND - Ligand Pharmaceuticals Incorporated | HOLD | 0 @ USD 198.41 | USD 0 | The current share valuation price of LGND based on adjusted close was USD 198.41. The average price that LGND shares were previous bought at was USD 126.392. The current market price is 57.0% higher than average price they were purchased at. The value of the holding in LGND has increased by USD 90,537 compared to the previous valuation of Ligand Pharmaceuticals Incorporated however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| LIVN - LivaNova PLC | HOLD | 0 @ USD 62.08 | USD 0 | The current share valuation price of LIVN based on adjusted close was USD 62.08. The average price that LIVN shares were previous bought at was USD 46.485. The current market price is 33.5% higher than average price they were purchased at. The value of the holding in LIVN has fallen by USD 65,851 compared to the previous valuation of LivaNova PLC |
| LNTH - Lantheus Holdings Inc | HOLD | 0 @ USD 64.84 | USD 0 | The current share valuation price of LNTH based on adjusted close was USD 64.84. The average price that LNTH shares were previous bought at was USD 76.9588. The current market price is -15.7% lower than average price they were purchased at. The value of the holding in LNTH has fallen by USD 33,993 compared to the previous valuation of Lantheus Holdings Inc |
| LONN.SW - | HOLD | 0 @ CHF 667.758 | CHF 0 | The current share valuation price of LONN.SW based on adjusted close was CHF 667.758. The average price that LONN.SW shares were previous bought at was CHF 640.611. The current market price is 4.2% higher than average price they were purchased at. The value of the holding in LONN.SW has increased by CHF 183,016 (USD $230,151) compared to the previous valuation of however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| MDT - Medtronic PLC | HOLD | 0 @ USD 98.48 | USD 0 | The current share valuation price of MDT based on adjusted close was USD 98.48. The average price that MDT shares were previous bought at was USD 90.2193. The current market price is 9.2% higher than average price they were purchased at. The value of the holding in MDT has increased by USD 30,847 compared to the previous valuation of Medtronic PLC however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| MEDP - Medpace Holdings Inc | HOLD | 0 @ USD 560.21 | USD 0 | The current share valuation price of MEDP based on adjusted close was USD 560.21. The average price that MEDP shares were previous bought at was USD 382.527. The current market price is 46.4% higher than average price they were purchased at. The value of the holding in MEDP has increased by USD 92,410 compared to the previous valuation of Medpace Holdings Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| MMS - LYXETFETUSITETFP | HOLD | 0 @ USD 87.26 | USD 0 | The current share valuation price of MMS based on adjusted close was USD 87.26. The average price that MMS shares were previous bought at was USD 75.2803. The current market price is 15.9% higher than average price they were purchased at. The value of the holding in MMS has fallen by USD 88,132 compared to the previous valuation of LYXETFETUSITETFP |
| MRK - Marks Electrical Group PLC | HOLD | 0 @ USD 100.69 | USD 0 | The current share valuation price of MRK based on adjusted close was USD 100.69. The average price that MRK shares were previous bought at was USD 80.8147. The current market price is 24.6% higher than average price they were purchased at. The value of the holding in MRK has increased by USD 279,792 compared to the previous valuation of Marks Electrical Group PLC however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| MRK - Merck & Company Inc | HOLD | 0 @ USD 100.69 | USD 0 | The current share valuation price of MRK based on adjusted close was USD 100.69. The average price that MRK shares were previous bought at was USD 80.8147. The current market price is 24.6% higher than average price they were purchased at. The value of the holding in MRK has increased by USD 279,792 compared to the previous valuation of Merck & Company Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| MRNA - Moderna Inc | HOLD | 0 @ USD 30.95 | USD 0 | The current share valuation price of MRNA based on adjusted close was USD 30.95. The average price that MRNA shares were previous bought at was USD 25.9653. The current market price is 19.2% higher than average price they were purchased at. The value of the holding in MRNA has increased by USD 208,529 compared to the previous valuation of Moderna Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| MRUS - Merus BV | HOLD | 0 @ USD 96.8 | USD 0 | The current share valuation price of MRUS based on adjusted close was USD 96.8. The average price that MRUS shares were previous bought at was USD 56.564. The current market price is 71.1% higher than average price they were purchased at. The value of the holding in MRUS has fallen by USD 6,969 compared to the previous valuation of Merus BV |
| MRVI - Maravai Lifesciences Holdings Inc | HOLD | 0 @ USD 3.52 | USD 0 | The current share valuation price of MRVI based on adjusted close was USD 3.52. The average price that MRVI shares were previous bought at was USD 2.97559. The current market price is 18.3% higher than average price they were purchased at. The value of the holding in MRVI has increased by USD 9,577 compared to the previous valuation of Maravai Lifesciences Holdings Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| MYGN - Myriad Genetics Inc | HOLD | 0 @ USD 6.7 | USD 0 | The current share valuation price of MYGN based on adjusted close was USD 6.7. The average price that MYGN shares were previous bought at was USD 8.64702. The current market price is -22.5% lower than average price they were purchased at. The value of the holding in MYGN has fallen by USD 27,814 compared to the previous valuation of Myriad Genetics Inc |
| NBIX - Neurocrine Biosciences Inc | HOLD | 0 @ USD 141.84 | USD 0 | The current share valuation price of NBIX based on adjusted close was USD 141.84. The average price that NBIX shares were previous bought at was USD 127.74. The current market price is 11.0% higher than average price they were purchased at. The value of the holding in NBIX has increased by USD 16,914 compared to the previous valuation of Neurocrine Biosciences Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| NEOG - Neogen Corporation | HOLD | 0 @ USD 7.47 | USD 0 | The current share valuation price of NEOG based on adjusted close was USD 7.47. The average price that NEOG shares were previous bought at was USD 9.99438. The current market price is -25.3% lower than average price they were purchased at. The value of the holding in NEOG has increased by USD 100,017 compared to the previous valuation of Neogen Corporation however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| NEU.AX - | HOLD | 0 @ AUD 12.8275 | AUD 0 | The current share valuation price of NEU.AX based on adjusted close was AUD 12.8275. The average price that NEU.AX shares were previous bought at was AUD 8.87049. The current market price is 44.6% higher than average price they were purchased at. The value of the holding in NEU.AX has fallen by AUD 52,642 (USD $34,752) compared to the previous valuation of |
| NOVN.SW - | HOLD | 0 @ CHF 135.693 | CHF 0 | The current share valuation price of NOVN.SW based on adjusted close was CHF 135.693. The average price that NOVN.SW shares were previous bought at was CHF 113.545. The current market price is 19.5% higher than average price they were purchased at. The value of the holding in NOVN.SW has fallen by CHF 23,252 (USD $29,240) compared to the previous valuation of |
| NTRA - Natera Inc | HOLD | 0 @ USD 224.74 | USD 0 | The current share valuation price of NTRA based on adjusted close was USD 224.74. The average price that NTRA shares were previous bought at was USD 176.324. The current market price is 27.5% higher than average price they were purchased at. The value of the holding in NTRA has fallen by USD 68,426 compared to the previous valuation of Natera Inc |
| NUVB - Nuvation Bio Inc | HOLD | 0 @ USD 8.99 | USD 0 | The current share valuation price of NUVB based on adjusted close was USD 8.99. The average price that NUVB shares were previous bought at was USD 6.64051. The current market price is 35.4% higher than average price they were purchased at. The value of the holding in NUVB has increased by USD 139,939 compared to the previous valuation of Nuvation Bio Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| NVAX - Novavax Inc | HOLD | 0 @ USD 6.68 | USD 0 | The current share valuation price of NVAX based on adjusted close was USD 6.68. The average price that NVAX shares were previous bought at was USD 6.53102. The current market price is 2.3% higher than average price they were purchased at. The value of the holding in NVAX has increased by USD 27,696 compared to the previous valuation of Novavax Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| NVAX - Hana Microelectronics Public Company Limited | HOLD | 0 @ USD 6.68 | USD 0 | The current share valuation price of NVAX based on adjusted close was USD 6.68. The average price that NVAX shares were previous bought at was USD 6.53102. The current market price is 2.3% higher than average price they were purchased at. The value of the holding in NVAX has increased by USD 27,696 compared to the previous valuation of Hana Microelectronics Public Company Limited however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| NVCR - Novocure Ltd | HOLD | 0 @ USD 12.56 | USD 0 | The current share valuation price of NVCR based on adjusted close was USD 12.56. The average price that NVCR shares were previous bought at was USD 16.4121. The current market price is -23.5% lower than average price they were purchased at. The value of the holding in NVCR has increased by USD 29,579 compared to the previous valuation of Novocure Ltd however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| ONT.L - Oxford Nanopore Technologies Ltd | HOLD | 0 @ GBP 1.69702 | GBP 0 | The current share valuation price of ONT.L based on adjusted close was GBP 1.69702. The average price that ONT.L shares were previous bought at was GBP 1.72772. The current market price is -1.8% lower than average price they were purchased at. The value of the holding in ONT.L has increased by GBP 18,312 (USD $24,492) compared to the previous valuation of Oxford Nanopore Technologies Ltd however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| PACB - Pacific Biosciences of California | HOLD | 0 @ USD 1.88 | USD 0 | The current share valuation price of PACB based on adjusted close was USD 1.88. The average price that PACB shares were previous bought at was USD 1.37661. The current market price is 36.6% higher than average price they were purchased at. The value of the holding in PACB has fallen by USD 18,465 compared to the previous valuation of Pacific Biosciences of California |
| PFE - Pfizer Inc | HOLD | 0 @ USD 25.04 | USD 0 | The current share valuation price of PFE based on adjusted close was USD 25.04. The average price that PFE shares were previous bought at was USD 24.3485. The current market price is 2.8% higher than average price they were purchased at. USD 0 compared to the previous valuation of Pfizer Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| PHARM.AS - Pharming Group NV | HOLD | 0 @ EUR 1.62653 | EUR 0 | The current share valuation price of PHARM.AS based on adjusted close was EUR 1.62653. The average price that PHARM.AS shares were previous bought at was EUR 0.896789. The current market price is 81.4% higher than average price they were purchased at. The value of the holding in PHARM.AS has fallen by EUR 17,264 (USD $20,272) compared to the previous valuation of Pharming Group NV |
| PHM.MC - Pharma Mar SA | HOLD | 0 @ EUR 86.8971 | EUR 0 | The current share valuation price of PHM.MC based on adjusted close was EUR 86.8971. The average price that PHM.MC shares were previous bought at was EUR 87.1976. The current market price is -0.3% lower than average price they were purchased at. The value of the holding in PHM.MC has increased by EUR 16,159 (USD $18,974) compared to the previous valuation of Pharma Mar SA however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| PME.AX - | HOLD | 0 @ AUD 142.141 | AUD 0 | The current share valuation price of PME.AX based on adjusted close was AUD 142.141. The average price that PME.AX shares were previous bought at was AUD 165.183. The current market price is -13.9% lower than average price they were purchased at. The value of the holding in PME.AX has fallen by AUD 209,903 (USD $138,567) compared to the previous valuation of |
| PODD - Insulet Corporation | HOLD | 0 @ USD 292.88 | USD 0 | The current share valuation price of PODD based on adjusted close was USD 292.88. The average price that PODD shares were previous bought at was USD 282.956. The current market price is 3.5% higher than average price they were purchased at. The value of the holding in PODD has increased by USD 167,019 compared to the previous valuation of Insulet Corporation however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| PRAX - Praxis Precision Medicines Inc | HOLD | 0 @ USD 269.26 | USD 0 | The current share valuation price of PRAX based on adjusted close was USD 269.26. The average price that PRAX shares were previous bought at was USD 167.342. The current market price is 60.9% higher than average price they were purchased at. The value of the holding in PRAX has increased by USD 85,126 compared to the previous valuation of Praxis Precision Medicines Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| PTCT - PTC Therapeutics Inc | HOLD | 0 @ USD 74.59 | USD 0 | The current share valuation price of PTCT based on adjusted close was USD 74.59. The average price that PTCT shares were previous bought at was USD 56.4444. The current market price is 32.1% higher than average price they were purchased at. The value of the holding in PTCT has fallen by USD 33,841 compared to the previous valuation of PTC Therapeutics Inc |
| QDEL - Quidel Corporation | HOLD | 0 @ USD 28.32 | USD 0 | The current share valuation price of QDEL based on adjusted close was USD 28.32. The average price that QDEL shares were previous bought at was USD 29.52. The current market price is -4.1% lower than average price they were purchased at. The value of the holding in QDEL has fallen by USD 87,292 compared to the previous valuation of Quidel Corporation |
| QIA.DE - QIAGEN NV | HOLD | 0 @ EUR 45.0845 | EUR 0 | The current share valuation price of QIA.DE based on adjusted close was EUR 45.0845. The average price that QIA.DE shares were previous bought at was EUR 43.4373. The current market price is 3.8% higher than average price they were purchased at. The value of the holding in QIA.DE has fallen by EUR 39,022 (USD $45,821) compared to the previous valuation of QIAGEN NV |
| RCUS - Arcus Biosciences Inc | HOLD | 0 @ USD 21.99 | USD 0 | The current share valuation price of RCUS based on adjusted close was USD 21.99. The average price that RCUS shares were previous bought at was USD 9.14068. The current market price is 140.6% higher than average price they were purchased at. The value of the holding in RCUS has fallen by USD 26,038 compared to the previous valuation of Arcus Biosciences Inc |
| RGEN - Repligen Corporation | HOLD | 0 @ USD 157.72 | USD 0 | The current share valuation price of RGEN based on adjusted close was USD 157.72. The average price that RGEN shares were previous bought at was USD 145.299. The current market price is 8.5% higher than average price they were purchased at. The value of the holding in RGEN has increased by USD 51,466 compared to the previous valuation of Repligen Corporation however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| RGNX - Regenxbio Inc | HOLD | 0 @ USD 13.51 | USD 0 | The current share valuation price of RGNX based on adjusted close was USD 13.51. The average price that RGNX shares were previous bought at was USD 8.67354. The current market price is 55.8% higher than average price they were purchased at. The value of the holding in RGNX has increased by USD 18,461 compared to the previous valuation of Regenxbio Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| RLAY - Relay Therapeutics Inc | HOLD | 0 @ USD 8.13 | USD 0 | The current share valuation price of RLAY based on adjusted close was USD 8.13. The average price that RLAY shares were previous bought at was USD 5.08308. The current market price is 59.9% higher than average price they were purchased at. The value of the holding in RLAY has increased by USD 17,237 compared to the previous valuation of Relay Therapeutics Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| RO.SW - | HOLD | 0 @ CHF 415.617 | CHF 0 | The current share valuation price of RO.SW based on adjusted close was CHF 415.617. The average price that RO.SW shares were previous bought at was CHF 370.354. The current market price is 12.2% higher than average price they were purchased at. The value of the holding in RO.SW has increased by CHF 6,869 (USD $8,638) compared to the previous valuation of however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| ROG.SW - | HOLD | 0 @ CHF 402.393 | CHF 0 | The current share valuation price of ROG.SW based on adjusted close was CHF 402.393. The average price that ROG.SW shares were previous bought at was CHF 324.411. The current market price is 24.0% higher than average price they were purchased at. The value of the holding in ROG.SW has increased by CHF 145,043 (USD $182,398) compared to the previous valuation of however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| RVTY - Revvity Inc. | HOLD | 0 @ USD 96.26 | USD 0 | The current share valuation price of RVTY based on adjusted close was USD 96.26. The average price that RVTY shares were previous bought at was USD 100.003. The current market price is -3.7% lower than average price they were purchased at. The value of the holding in RVTY has fallen by USD 73,690 compared to the previous valuation of Revvity Inc. |
| RXRX - Recursion Pharmaceuticals Inc | HOLD | 0 @ USD 4.44 | USD 0 | The current share valuation price of RXRX based on adjusted close was USD 4.44. The average price that RXRX shares were previous bought at was USD 5.14428. The current market price is -13.7% lower than average price they were purchased at. The value of the holding in RXRX has fallen by USD 115,719 compared to the previous valuation of Recursion Pharmaceuticals Inc |
| RYTM - Rhythm Pharmaceuticals Inc | HOLD | 0 @ USD 111.73 | USD 0 | The current share valuation price of RYTM based on adjusted close was USD 111.73. The average price that RYTM shares were previous bought at was USD 67.8137. The current market price is 64.8% higher than average price they were purchased at. The value of the holding in RYTM has fallen by USD 9,211 compared to the previous valuation of Rhythm Pharmaceuticals Inc |
| SDGR - Schrodinger Inc | HOLD | 0 @ USD 17.2 | USD 0 | The current share valuation price of SDGR based on adjusted close was USD 17.2. The average price that SDGR shares were previous bought at was USD 22.5384. The current market price is -23.7% lower than average price they were purchased at. The value of the holding in SDGR has fallen by USD 14,154 compared to the previous valuation of Schrodinger Inc |
| SECT-B.ST - | HOLD | 0 @ SEK 27.2012 | SEK 0 | The current share valuation price of SECT-B.ST based on adjusted close was SEK 27.2012. The average price that SECT-B.ST shares were previous bought at was SEK 28.0136. The current market price is -2.9% lower than average price they were purchased at. The value of the holding in SECT-B.ST has increased by SEK 44,136 (USD $4,747) compared to the previous valuation of however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| SFZN.SW - | HOLD | 0 @ CHF 93.9547 | CHF 0 | The current share valuation price of SFZN.SW based on adjusted close was CHF 93.9547. The average price that SFZN.SW shares were previous bought at was CHF 123.569. The current market price is -24.0% lower than average price they were purchased at. The value of the holding in SFZN.SW has increased by CHF 175,382 (USD $220,551) compared to the previous valuation of however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| SLP - Sylvania Platinum Limited | HOLD | 0 @ USD 18.56 | USD 0 | The current share valuation price of SLP based on adjusted close was USD 18.56. The average price that SLP shares were previous bought at was USD 26.1345. The current market price is -29.0% lower than average price they were purchased at. The value of the holding in SLP has fallen by USD 2,585 compared to the previous valuation of Sylvania Platinum Limited |
| SRPT - Sarepta Therapeutics Inc | HOLD | 0 @ USD 20.34 | USD 0 | The current share valuation price of SRPT based on adjusted close was USD 20.34. The average price that SRPT shares were previous bought at was USD 45.0034. The current market price is -54.8% lower than average price they were purchased at. The value of the holding in SRPT has fallen by USD 98,284 compared to the previous valuation of Sarepta Therapeutics Inc |
| SRT3.DE - Sartorius AG | HOLD | 0 @ EUR 278.516 | EUR 0 | The current share valuation price of SRT3.DE based on adjusted close was EUR 278.516. The average price that SRT3.DE shares were previous bought at was EUR 247.576. The current market price is 12.5% higher than average price they were purchased at. The value of the holding in SRT3.DE has increased by EUR 16,147 (USD $18,960) compared to the previous valuation of Sartorius AG however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| STOK - Stoke Therapeutics Inc | HOLD | 0 @ USD 31.93 | USD 0 | The current share valuation price of STOK based on adjusted close was USD 31.93. The average price that STOK shares were previous bought at was USD 12.0607. The current market price is 164.7% higher than average price they were purchased at. The value of the holding in STOK has fallen by USD 61,226 compared to the previous valuation of Stoke Therapeutics Inc |
| SUPN - Supernus Pharmaceuticals Inc | HOLD | 0 @ USD 49.28 | USD 0 | The current share valuation price of SUPN based on adjusted close was USD 49.28. The average price that SUPN shares were previous bought at was USD 36.2354. The current market price is 36.0% higher than average price they were purchased at. The value of the holding in SUPN has increased by USD 36,129 compared to the previous valuation of Supernus Pharmaceuticals Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| TECH - Bio-Techne Corp | HOLD | 0 @ USD 57.1 | USD 0 | The current share valuation price of TECH based on adjusted close was USD 57.1. The average price that TECH shares were previous bought at was USD 59.3169. The current market price is -3.7% lower than average price they were purchased at. The value of the holding in TECH has increased by USD 21,139 compared to the previous valuation of Bio-Techne Corp however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| TECN.SW - | HOLD | 0 @ CHF 159.824 | CHF 0 | The current share valuation price of TECN.SW based on adjusted close was CHF 159.824. The average price that TECN.SW shares were previous bought at was CHF 197.12. The current market price is -18.9% lower than average price they were purchased at. The value of the holding in TECN.SW has increased by CHF 64,934 (USD $81,657) compared to the previous valuation of however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| TGTX - TG Therapeutics Inc | HOLD | 0 @ USD 29.93 | USD 0 | The current share valuation price of TGTX based on adjusted close was USD 29.93. The average price that TGTX shares were previous bought at was USD 33.8235. The current market price is -11.5% lower than average price they were purchased at. The value of the holding in TGTX has fallen by USD 210,942 compared to the previous valuation of TG Therapeutics Inc |
| TMO - Time Out Group plc | HOLD | 0 @ USD 562.39 | USD 0 | The current share valuation price of TMO based on adjusted close was USD 562.39. The average price that TMO shares were previous bought at was USD 418.499. The current market price is 34.4% higher than average price they were purchased at. The value of the holding in TMO has fallen by USD 6,182 compared to the previous valuation of Time Out Group plc |
| TNDM - Tandem Diabetes Care Inc | HOLD | 0 @ USD 21.8 | USD 0 | The current share valuation price of TNDM based on adjusted close was USD 21.8. The average price that TNDM shares were previous bought at was USD 21.1386. The current market price is 3.1% higher than average price they were purchased at. The value of the holding in TNDM has fallen by USD 52,108 compared to the previous valuation of Tandem Diabetes Care Inc |
| TWST - Twist Bioscience Corp | HOLD | 0 @ USD 31.92 | USD 0 | The current share valuation price of TWST based on adjusted close was USD 31.92. The average price that TWST shares were previous bought at was USD 36.2456. The current market price is -11.9% lower than average price they were purchased at. The value of the holding in TWST has fallen by USD 14,502 compared to the previous valuation of Twist Bioscience Corp |
| TXG - 10X Genomics Inc | HOLD | 0 @ USD 16 | USD 0 | The current share valuation price of TXG based on adjusted close was USD 16. The average price that TXG shares were previous bought at was USD 12.5355. The current market price is 27.6% higher than average price they were purchased at. The value of the holding in TXG has increased by USD 33,502 compared to the previous valuation of 10X Genomics Inc however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| TXG - Terex Corporation | HOLD | 0 @ USD 16 | USD 0 | The current share valuation price of TXG based on adjusted close was USD 16. The average price that TXG shares were previous bought at was USD 12.5355. The current market price is 27.6% higher than average price they were purchased at. The value of the holding in TXG has increased by USD 33,502 compared to the previous valuation of Terex Corporation however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| UCB.BR - UCB SA | HOLD | 0 @ EUR 277.226 | EUR 0 | The current share valuation price of UCB.BR based on adjusted close was EUR 277.226. The average price that UCB.BR shares were previous bought at was EUR 208.203. The current market price is 33.2% higher than average price they were purchased at. The value of the holding in UCB.BR has increased by EUR 70,283 (USD $82,529) compared to the previous valuation of UCB SA however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| VCYT - Veracyte Inc | HOLD | 0 @ USD 42.04 | USD 0 | The current share valuation price of VCYT based on adjusted close was USD 42.04. The average price that VCYT shares were previous bought at was USD 34.3612. The current market price is 22.3% higher than average price they were purchased at. The value of the holding in VCYT has fallen by USD 15,309 compared to the previous valuation of Veracyte Inc |
| VIR - Vir Biotechnology Inc | HOLD | 0 @ USD 5.93 | USD 0 | The current share valuation price of VIR based on adjusted close was USD 5.93. The average price that VIR shares were previous bought at was USD 7.32775. The current market price is -19.1% lower than average price they were purchased at. The value of the holding in VIR has fallen by USD 26,106 compared to the previous valuation of Vir Biotechnology Inc |
| VIR - Vidrala S.A | HOLD | 0 @ USD 5.93 | USD 0 | The current share valuation price of VIR based on adjusted close was USD 5.93. The average price that VIR shares were previous bought at was USD 7.32775. The current market price is -19.1% lower than average price they were purchased at. The value of the holding in VIR has fallen by USD 26,106 compared to the previous valuation of Vidrala S.A |
| VLA.PA - Valneva SE | HOLD | 0 @ EUR 4.09272 | EUR 0 | The current share valuation price of VLA.PA based on adjusted close was EUR 4.09272. The average price that VLA.PA shares were previous bought at was EUR 2.91512. The current market price is 40.4% higher than average price they were purchased at. The value of the holding in VLA.PA has fallen by EUR 14,594 (USD $17,137) compared to the previous valuation of Valneva SE |
| VNDA - Vanda Pharmaceuticals Inc | HOLD | 0 @ USD 6.67 | USD 0 | The current share valuation price of VNDA based on adjusted close was USD 6.67. The average price that VNDA shares were previous bought at was USD 4.65578. The current market price is 43.3% higher than average price they were purchased at. The value of the holding in VNDA has fallen by USD 10,321 compared to the previous valuation of Vanda Pharmaceuticals Inc |
| VRDN - Viridian Therapeutics Inc | HOLD | 0 @ USD 31.6 | USD 0 | The current share valuation price of VRDN based on adjusted close was USD 31.6. The average price that VRDN shares were previous bought at was USD 30.1226. The current market price is 4.9% higher than average price they were purchased at. The value of the holding in VRDN has fallen by USD 54,079 compared to the previous valuation of Viridian Therapeutics Inc |
| XVIVO.ST - | HOLD | 0 @ SEK 20.0294 | SEK 0 | The current share valuation price of XVIVO.ST based on adjusted close was SEK 20.0294. The average price that XVIVO.ST shares were previous bought at was SEK 40.1806. The current market price is -50.2% lower than average price they were purchased at. The value of the holding in XVIVO.ST has increased by SEK 5,674 (USD $610) compared to the previous valuation of however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |
| ZYME - Zymeworks Inc. Common Stock | HOLD | 0 @ USD 26.4 | USD 0 | The current share valuation price of ZYME based on adjusted close was USD 26.4. The average price that ZYME shares were previous bought at was USD 17.6935. The current market price is 49.2% higher than average price they were purchased at. The value of the holding in ZYME has increased by USD 50,619 compared to the previous valuation of Zymeworks Inc. Common Stock however if the holding was sold on 2025-12-18 this would crystalise an overall loss. |